It’s also a pity that we haven’t yet build a connection between circulating lymphocyte subsets and the authentic tumor immune microenvironment or widely acknowledged efficacy markers of immunotherapy, such as PD-L1 expression level in tumor tissue samples. This evidence concerns the gene CD274 and neoplasm.